These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
406 related articles for article (PubMed ID: 31387063)
1. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. Wei H; Duan Y; Gou W; Cui J; Ning H; Li D; Qin Y; Liu Q; Li Y Eur J Med Chem; 2019 Nov; 181():111552. PubMed ID: 31387063 [TBL] [Abstract][Full Text] [Related]
2. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity. Liu F; Tang B; Liu H; Li L; Liu G; Cheng Y; Xu Y; Chen W; Huang Y Anticancer Agents Med Chem; 2016; 16(12):1652-1664. PubMed ID: 27039919 [TBL] [Abstract][Full Text] [Related]
3. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo. Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358 [TBL] [Abstract][Full Text] [Related]
4. Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2. Zhang HQ; Gong FH; Ye JQ; Zhang C; Yue XH; Li CG; Xu YG; Sun LP Eur J Med Chem; 2017 Jan; 125():245-254. PubMed ID: 27688180 [TBL] [Abstract][Full Text] [Related]
5. Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors. Zhang HQ; Gong FH; Li CG; Zhang C; Wang YJ; Xu YG; Sun LP Eur J Med Chem; 2016 Feb; 109():371-9. PubMed ID: 26826581 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886 [TBL] [Abstract][Full Text] [Related]
7. Pharmacophore based drug design and synthesis of oxindole bearing hybrid as anticancer agents. Pathak A; Pandey V; Raj Pokharel Y; Devaraji V; Ali A; Haider K; Saad S; Dewangan RP; Siddiqui N; Shahar Yar M Bioorg Chem; 2021 Nov; 116():105358. PubMed ID: 34544029 [TBL] [Abstract][Full Text] [Related]
8. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents. Sadek MM; Serrya RA; Kafafy AH; Ahmed M; Wang F; Abouzid KA J Enzyme Inhib Med Chem; 2014 Apr; 29(2):215-22. PubMed ID: 23402383 [TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme. El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological study of 4-[(2-nitroimidazole-1 Cheng W; Wang S; Yang Z; Tian X; Hu Y Drug Des Devel Ther; 2019; 13():3079-3089. PubMed ID: 31695326 [TBL] [Abstract][Full Text] [Related]
11. Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia. Cheng W; Yuan Y; Qiu N; Peng P; Sheng R; Hu Y Bioorg Med Chem; 2014 Dec; 22(24):6796-805. PubMed ID: 25468044 [TBL] [Abstract][Full Text] [Related]
12. Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking. Xi L; Zhang JQ; Liu ZC; Zhang JH; Yan JF; Jin Y; Lin J Org Biomol Chem; 2013 Jul; 11(26):4367-78. PubMed ID: 23715382 [TBL] [Abstract][Full Text] [Related]
13. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile. Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701 [TBL] [Abstract][Full Text] [Related]
14. Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments. Wang R; Liu H; You YY; Wang XY; Lv BB; Cao LQ; Xue JY; Xu YG; Shi L Bioorg Med Chem Lett; 2021 Mar; 36():127788. PubMed ID: 33460739 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers. Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140 [TBL] [Abstract][Full Text] [Related]
16. Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer. Choudhary S; Doshi A; Luckett-Chastain L; Ihnat M; Hamel E; Mooberry SL; Gangjee A Bioorg Med Chem; 2021 Apr; 35():116061. PubMed ID: 33647840 [TBL] [Abstract][Full Text] [Related]
17. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2. Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor. Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742 [TBL] [Abstract][Full Text] [Related]
19. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents. Yassen AS; Elshihawy HE; Said MM; Abouzid KA Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of novel hybrids between 4-anilinoquinazolines and substituted triazoles as potent cytotoxic agents. Le-Nhat-Thuy G; Dinh TV; Pham-The H; Nguyen Quang H; Nguyen Thi N; Dang Thi TA; Hoang Thi P; Le Thi TA; Nguyen HT; Nguyen Thanh P; Le Duc T; Nguyen TV Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3741-3747. PubMed ID: 30337229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]